Antagonism Of Endothelin Action Normalizes Altered Levels Of VEGF And Its Signaling In The Brain Of Stroke-Prone Spontaneously Hypertensive Rat by Mowa, Chishimba Nathan & NC DOCKS at Appalachian State University
Archived version from NCDOCKS Institutional Repository http://libres.uncg.edu/ir/asu/ 
Antagonism Of Endothelin Action Normalizes Altered 
Levels Of VEGF And Its Signaling In The Brain Of 
Stroke-Prone Spontaneously Hypertensive Rat
Authors
Subrina Jesmin , Seiji Maeda, Chishimba N. Mowa, Sohel Zaedi, Hiroko Togashi, Shamsul H. Prodhan, Taku 
Yamaguchi, Mitsuhiro Yoshioka, Ichiro Sakuma, Takashi Miyauchi &Norihiro Kato 
Abstract 
Stroke-prone spontaneously hypertensive rats (SHRSP) often suffer from spontaneous stroke, in part, due to 
abnormalities in the cerebrovasculature. Here, we investigate the profile of key angiogenic factors and their basic 
signaling molecules in the brain of SHRSP during the age-dependent stages of hypertension. The profile of VEGF 
and its receptor, Flk-1, was dependent on age and stage of hypertension (i.e., down regulated at pre-hypertensive and 
malignant hypertensive stages, but up regulated at typical hypertensive stage), while that of its downstream 
components, pAkt and eNOS, were down regulated in a time-dependent manner in the frontal cortex of SHRSP 
compared to age-matched genetic control, normotensive WKY rats. On the other hand, the expression of 
endothelin-1 and its type A receptor (endothelin ETA receptor) were up regulated, depending on age and stage of 
hypertension. In contrast, levels of endothelin type B receptor were down regulated. The regional cerebral blood flow 
decreased during the development of malignant hypertension. Thus, subsequent experiments were designed to 
investigate whether endothelin-1 receptor antagonism, using endothelin-A/-B dual receptor antagonist SB209670, 
could normalize the molecular profile of these factors in SHRSP brain. Interestingly, blockage of endothelin-1 
receptor restored to normal, levels of cerebral endothelin-1, endothelin ETA receptor and endothelin ETB receptor; 
VEGF and Flk-1; endothelial nitric oxide synthase (eNOS) and pAkt, in SHRSP, compared to age-matched WKY. 
Endothelin receptor blocker might be important to prevent the progression in the defect in VEGF and its angiogenic 
signaling cascade in the pathogenesis of hypertension-induced vascular remodeling in frontal cortex of SHRSP rats.
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1. Introduction
The stroke-prone spontaneously hypertensive rat (SHRSP), a 
substrain of SHR developed by selective breeding (Okamoto 
et al., 1974), is a recently characterized animal model. This 
model (SHRSP) has a great potential for use in studies aimed at 
understanding mechanisms that may underlie the pathogenesis 
of human cerebrovascular disorders, such as genetic hyperten- 
sion, but most notably stroke, hence its name, “stroke-prone” 
SHR. As in humans, stroke in the SHRSP is complex, polygenic 
and is caused by multiple factors, but particularly by the pre- 
sence of hypertension (Gratton et al., 1998; Virgintino et al., 
2003). Because the SHRSP is a suitable animal model for 
both hypertension and stroke, it is an ideal model for studying 
the relationship and interaction between the two vascular 
disorders. 
The development of hypertension in SHRSP is well estab- 
lished and has been divided into three consecutive stages, namely 
prehypertensive, typical hypertensive and malignant hyper- 
tensive, which ultimately may lead to stroke. However, the 
expression or profile and involvement of key vaso-regulatory 
factors, such as vascular endothelial growth factor (VEGF) and 
endothelin during the three key stages of hypertension and in 
different age-groups of SHRSP brain, is not known. 
VEGF is an endothelial mitogen, angiogenic and potent 
vasopermeability factor that mediates its effects mainly through 
two VEGF receptor tyrosine kinases, namely fetal liver kinase 1 
(Flk-1) and fms-like tyrosine kinase 1 (Flt-1) (Ferrara, 2001). 
Importantly, VEGF has been shown to have a diverse role in 
ischemic stroke, as administration of VEGF enhances angio- 
genesis in the ischemic brain, leading to improved neurological 
recovery (Zhang et al., 2000). The pattern of VEGF expression 
and its receptors, following occlusion of the middle cerebral 
artery in the rat brain, have been studied by a number of 
investigators (Kovacs et al., 1996; Hayashi et al., 1997; 
Lennmyr et al., 1988). Its been demonstrated that VEGF levels 
increase within the ischemic area and is localized in most cell 
types, such as neurons and glia, as well as infiltrating macro- 
phages. However, because of its potent effects on vascular 
permeability, increased VEGF levels in the ischemic regions of 
the brain leads to undesirable effects, including formation of 
cerebral edema, increased intracranial pressure and impaired 
perfusion of the affected area, and ultimately to the development 
of infarcts (Carmeliet and Storkebaum, 2002). Moreover, intra- 
venous infusion of recombinant human (rh) VEGF165 imme- 
diately ( 1 h) after onset of focal cerebral embolic ischemia, 
induce leakage of the blood–brain barrier, with resultant hemor- 
rhagic transformation of the ischemic lesions (Zhang et al., 
2000). Thus, a potential role of VEGF in different cerebral 
pathologies is well-documented. However, the expression or 
dynamics of VEGF signaling during the key stages of hyper- 
tension and in different age-groups of rats in the brain of 
SHRSP is unknown. 
Because of the potent vasoconstrictive actions of endothelin- 
1 and its upregulation after stroke, this peptide has been im- 
plicated in the pathogenesis of ischemic brain lesions (Macrae 
et al., 1993; Patel, 1996; Lampl et al., 1997). Endothelin-1, a 
potent vasoconstrictor with vasoproliferative activity, is impor- 
tant in the development of hypertension and in target-organ 
damage in salt-loaded SHRSP (Okada et al., 1995; Blezer et al., 
1999). A chronic blockade of the endothelin type A receptor 
(endothelin ETA receptor) in salt-loaded SHRSP, using a non- 
peptide antagonist, markedly increased survival, attenuated the 
development of hypertension, and prevented cerebral edema and 
renal damage (Blezer et al., 1999). However, as with VEGF 
signaling, the profile of endothelin-1 signaling during the devel- 
opment of hypertension and in different age-groups in the brain 
of SHRSP has not been clarified. 
Endothelin-1 and nitric oxide (NO) are now recognized as 
important endothelial-derived vasomediators, the former induc- 
ing vasoconstriction and the later vasodilation (Donckier et al., 
1991; Palmer et al., 1987). In addition to their role in modu- 
lating vascular tone, both could be involved in various disease 
processes. Of interest or importance to the present study, several 
studies have reported an interaction between VEGF and these 
two molecules (endothelin-1 and NO): 1) endothelin-1 induces 
levels of VEGF by increasing hypoxia-inducible factor-1α in 
ovarian carcinoma cells (Spinella et al., 2002), whereas in breast 
cancer, endothelin-1 expression has been correlated with 
neovascularization and high levels of VEGF (Wulfing et al., 
2004), 2). The relationship between VEGF and NO is relatively 
better understood and is known to be context-dependent, i.e., 
depending on the context, NO either up regulates or down 
regulates VEGF expression (Kimura and Esumi, 2003). How- 
ever, the relationship between endothelin-1 and VEGF in the 
brain tissues of animal models of genetic hypertension, such as 
in SHRSP, is unknown. 
Such knowledge, i.e., interaction between and pattern of 
VEGF and endothelin-1 profile during the pre-stroke phases in 
SHRSP, may provide critical insights that may help elucidate 
mechanisms that underlie the pathogenesis of stroke. Thus, the 
present study was designed to investigate the profile of these 
two vaso-regulatory factors and their basic signaling molecules 
in the brain of SHRSP during the three age-dependent stages of 
hypertension. Secondly, we studied their potential interaction 
using a dual endothelin-1 receptor blocker administered from 
the pre-hypertensive stage. 
2. Materials and methods
2.1. Animal models and treatments 
The present study utilized SHRSP (n = 25), SHR (n = 25) 
(Sankyo Labo Service, Tokyo, Japan) and normotensive control 
WKY (n = 25) rats aged 6, 20 and 40 weeks old. SHRSP and 
normotensive rats were originally donated by the late Prof Kozo 
Okamoto, Department of Pathology, Kinki University School of 
Medicine, Osaka, Japan, and inbred in our laboratory (current 
generation F57). All animals were housed in a room maintained 
at temperature, 22 ± 2 °C; relative humidity, 55 ± 10%: and 
12-h light/dark cycle (lights on at 6:00 AM). The animals 
were allowed free access to food and water. The experimen- 
tal design was approved by the Animal Care and Use 
Committees of Hokkaido University School of Medicine and 
Tsukuba University. 
Following the various treatments described below, the rats were 
killed by exsanguinations under a lethal anaesthetic dose of 
ketamine, and the whole brain was rapidly excised and immediately 
frozen in liquid nitrogen and stored at −80 °C for later use. 
2.2. Treatments 
Group 1: the blood pressure of SHRSP, SHR and WKY rats 
aged 6, 20, 40 weeks was measured using the tail-cuff method. 
The rats were then killed and their frontal cortices processed, as 
described above. 
Group 2: in another set of experiments, 6-week old SHRSP rats 
were either given an endothelin dual receptor antagonist, 
SB209670 [(+)-(1S,2R,3S)-3-(2-carboxymethoxy4-methoxyphe- 
nyl)-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2- 
carboxylic acid] (n = 15) (1 mg/day: SmithKline Beecham 
Pharmaceuticals, PA, U.S.A.), or saline (n = 15) (vehicle), sub- 
cutaneously using an osmotic pump (Model 2ML4, DURECT 
Corporation, Cupertino, CA, U.S.A.), implanted in the back. The 
rats were treated for 12 weeks and examined at 18 weeks, a time 
when they were in the typical hypertensive stage. Control rats, 
WKY rats (n = 15), were inserted with osmotic pumps containing 
saline. 
Group 3: in another setting, some control WKY rats 
were treated with dual endothelin receptor antagonist, 
SB209670, as described for group 2 above (n = 6 for each 
group). 
2.3. Monitoring of regional cerebral blood flow 
Rats were anesthetized with 1% halothane in 20% O2/N2, 
and concentric guide cannulae were stereotactically implanted 
to the surface of the duramater of the right prefrontal cortex 
(3.2 mm anterior and 0.7 mm lateral to the bregma), according 
to the stereotaxic co-ordinates. Two days after implantation, a 
fiber-optic probe with a diameter of 0.5 mm (Omegawave, 
Tokyo, Japan) was inserted via the guide cannula, and re- 
gional cerebral blood flow was measured using a laser- 
Doppler flowmetry (Omegaflow FLO-C1; Omegawave, 
Tokyo, Japan), under freely moving conditions (Jesmin 
et al., 2004). The average of the value obtained every 0.5 s 
for 5 min (600 points) was evaluated as a basal regional 
cerebral blood flow. 
2.4. Enzyme immunoassay for endothelin-1 
The concentrations of endothelin-1 in plasma and extracts of 
the frontal cortex of both treated and untreated rats were deter- 
mined using an Endothelin-1 Enzyme Immuno Assay Kit 
(Immuno-Biological Laboratories, Fujioka, Japan). The 
reported cross-reactivity of the antibody for the former was 
0.1% for all the endothelins, 0.1% for endothelin-3, and 
3.3% for endothelin-2. 
2.5. Western blot analysis 
Changes in levels of the proteins of interest were determined 
by immunoblotting, as demonstrated in our previous report 
(Jesmin et al., 2004). Briefly, samples of tissue homogenate 
were subjected to electrophoresis on polyacrylamide gels, and 
proteins were transferred to polyvinylidine difloride filter 
membrane. After blocking with 5% non-fat milk in phosphate- 
buffered saline, the membranes were incubated with specific 
antibodies recognizing either VEGF (Immunological Labora- 
tories, Fujioka, Japan), Flk-1 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), phosphorylated Akt (pAkt) (Cell Signaling 
Technology, Beverly, MA, USA), endothelial nitric oxide 
synthase (eNOS) (Affinity BioReagents, Golden, CT, USA), 
endothelin ETA receptor (Alomone Labs, Jerusalem, Israel), or 
endothelin ETB receptor (Alomone Labs) antibodies. Two 
antibodies for VEGF, namely mouse anti-human VEGF anti- 
body (Santa Cruz Biotechnology) and anti-human VEGF rabbit 
polyclonal antibody (Immunobiological Laboratories), were 
used in the present study to detect VEGF by immunoblot 
analysis. These antibodies recognize both the 165 and 121 
amino acid residue forms of VEGF and were able to recognize 
the target peptide in rats. In most cases, the specificity of each 
antibody was confirmed in preliminary studies by blocking 
their immunoreactivity using specific competing peptides 
against which the antibodies were raised. It should also be 
noted that immunoreactivity disappeared when non-immune 
IgG was used instead of the primary antibodies. After exten- 
sive washing with phosphate-buffered saline containing 0.1% 
Tween 20, designed to remove any nonspecifically bound 
primary antibodies, the membranes were incubated with 
horseradish peroxidase-conjugated anti-rabbit antibody. Negli- 
gible loading/transfer variation was observed between sam- 
ples. Moreover, β-Actin was used as a loading control (anti- 
Fig. 1. (A) Systolic blood pressure (n = 20 for each group), (B), diastolic blood 
pressure (n = 20 for each group) and (C) measurement of regional cerebral blood 
flow in the frontal cortex of WKY (n = 5), SHRSP (n = 5) and SHR (n = 5) from 6 
to 40 weeks of age. Regional cerebral blood flow has been expressed as ml/min/ 
100 g tissue. Data are means± S.D. ⁎p 0.05 compared with the corresponding
values obtained in WKY at each respective age. 
Xenopus laevis β-Actin mouse monoclonal antibody, Abcam). 
The blots were visualized with the enhanced chemi- 
luminescence detection system (Amersham Biosciences UK, 
Little Chalfont, Buckinghamshire, UK), exposed to X-ray film, 
and analyzed by NIH image software. 
2.6. RNA preparation and real-time quantitative PCR 
Real-time quantitative PCR was performed, according to the 
protocols and primer sequences described in our recent report 
(Jesmin et al., 2004). 
2.7. Capillary morphology 
Previous studies have shown that histochemical staining 
with the lectin Griffonia simplicifolia (GSA-B4) is a sensitive 
and reliable method to visualize the capillary vasculature in 
the frontal cortex of rat brain (Jesmin et al., 2003). Eight- 
micrometer-thick serial frozen coronal sections of frontal 
cortex were stained with GSA-B4 (Sigma Chemical, St. 
Louis, MO). The sections were fixed in acetone, air dried, and 
placed in PBS. After treatment with 3% H2O2 in methanol and 
washing in PBS, the sections were incubated with GSA-B4 
Fig. 2. (A) Endothelin-1 levels in frontocortical tissues of WKY, SHRSP and SHR from 6 to 40 weeks of age. Tissue endothelin-1 level was determined by ELISA. (B, 
C), Immunoblot analyses for endothelin ETA receptor and endothelin ETB receptor, respectively, in the frontocortical tissues of WKY, SHRSP and SHR rats from 6 to 
40 weeks of age with representative blots and densitometries, respectively. The experiments were conducted by loading equal amounts of WKY, SHRSP and SHR 
frontocortical proteins in each lane. β-Actin was used as loading control. The protein level of each band obtained in 20-week-old WKY is normalized as 1.0. Values are 
means± S.D. of 8 preparations from different animals in each group. ⁎p 0.01 vs. age-matched WKY.
(1:100 dilution in PBS) overnight at 4 °C. This was im- 
mediately followed by reaction with streptoavidin conjugated 
to peroxidase (Nichirei Corp., Tokyo, Japan), rinsing in PBS 
and visualization using diaminobenzidine/H2O2 as a chromo- 
gen. To enhance the diaminobenzidine reaction, the sections 
were rinsed with 0.05 M NaHCO3 (pH 9.6) and then incu- 
bated in diaminobenzidine enhancing solution (Vector Labo- 
ratories, Burlingame, CA). Vascular endothelium was stained 
with lectin, which stained capillaries as black/dark brown 
dots. Sections were examined using a microscope (Olympus, 
Tokyo, Japan), and counts were made of stained capillaries in 
cross-sections in 30 fields (117,617 μm2/field) per sample 
(section on slide) at a final magnification of × 400 by an 
image-analyzing software (microcomputer imaging device, 
Imaging Research, St. Catharine, Ontario, Canada). This 
counting method has been well established by previous 
reports (Jesmin et al., 2003, 2002a,b). Furthermore, the 
number of lectin-stained capillaries were quantified by two 
independent researchers in a double-blinded study. Care was 
taken to avoid counting the same single capillary twice. Any 
microvessel (defined as a vessel having internal diameter 
100 μm) that had no apparent lumen was considered as a 
single capillary. 
2.8. Immunohistochemical studies 
Immunohistochemical labeling of frontocortical tissues were 
performed, as described in our previous study (Jesmin et al., 
2003, 2002a,b). Briefly, after tissues were cut (5 μm thick), the 
sections were deparaffinized and treated for 20 min with citrate 
buffer (10 mM citric acid, pH 6.0) in a microwave oven (750 W) 
before immunostaining. In some cases, frozen sections were 
fixed in acetone and air dried. After blocking non-specific 
staining from secondary antibodies, the sections were incubated 
with primary antibodies overnight at 4 °C, followed by 
incubation with appropriate secondary antibodies coupled to 
horseradish peroxidase. The immunostaining findings were 
then viewed by light microscopy by incubating tissue sections 
with AEC (3-amino-9-ethylcarbazole) Peroxidase Substrate 
Solution. 
Fig. 3. Representative Western blots of VEGF (A) and Flk-1 (B) with densitometric analyses in frontocortical tissues from WKY, SHR, and SHRSP from 6 to 40 weeks 
of age. The protein level of each band obtained in 20-week-old WKY is normalized as 1.0. Values are means± S.D. of 8 preparations from different animals in each 
group. ⁎p 0.01 vs. age-matched WKY.
2.9. Statistical analysis 
The values are expressed as means ± S.D. Statistical analysis 
of the data was performed by one way analysis of variance 
(ANOVA), followed by Fisher's protected least significance 
t-test and Scheffé's test to determine the significance of the 
differences in multiple comparisons. A p-value less than 0.05 
was considered significant. 
3. Results
Part 1 summarizes data demonstrating age-dependent 
alterations in blood pressure, cerebral blood flow, and signaling 
transductions of VEGF and endothelin-1. 
3.1. Blood pressure changes 
Systolic blood pressure of SHRSP increased with age, 
reaching 276 ± 14 mmHg (n = 20) at 40 weeks of age (Fig. 1A). 
At 6 weeks of age, the blood pressure of SHRSP was already 
higher than that of WKY (168 ± 17 vs. 132 ± 8 mmHg, p 0.05). 
Although the systolic blood pressure of SHR was consistently 
found to be significantly higher than that of WKY, hypertension 
in SHR was established at the age of 20 weeks (Fig. 1A). 
The diastolic blood pressure was always significantly higher 
in SHRSP rats at all the ages examined than in WKY rats 
(Fig. 1B). 
3.2. Measurements of regional cerebral blood flow 
A significant decrease of regional cerebral blood flow 
was observed in SHRSP frontal cortex at 6 weeks and 35– 
40 weeks of age, compared to age-matched WKY. At the typical 
hypertensive stage (18–20 weeks of age) in SHRSP, regional 
cerebral blood flow tended to decrease, although it was 
statistically insignificant compared to age-matched WKY. How- 
ever, changes in regional cerebral blood flow of SHR were 
insignificant at all the ages compared to age-matched WKY 
(Fig. 1C). 
3.3. Endothelin-1 level and expression of endothelin receptors 
Endothelin-1 levels in the frontal cortex of both SHRSP and 
SHR increased in a time-dependent manner compared to age- 
Fig. 4. Representative Western blots of pAkt (A) and eNOS (B) with densitometric analyses in frontocortical tissues from WKY, SHR, and SHRSP from 6 to 40 weeks 
of age. The protein level of each band obtained in 20-week-old WKY is normalized as 1.0. Values are means± S.D. of 8 preparations from different animals in each 
group. ⁎p 0.01 vs. age-matched WKY.
matched WKY (Fig. 2A). However, the extent of the increase 
was greater in SHRSP than in SHR (Fig. 2A). 
Levels of endothelin ETA receptor were up regulated in 
SHRSP frontal cortex, along with its peptide ligand, endothelin- 
1, from the prehypertensive stage to malignant hypertensive 
stage, compared to age-matched WKY (Fig. 2B). In contrast, 
those of endothelin ETB receptor were down regulated in a 
time-dependent manner (Fig. 2C). The expression patterns of 
endothelin receptors were different in SHR frontal cortex from 
those of SHRSP (Fig. 2). 
3.4. Expression of VEGF and Flk-1 
Levels of VEGF and Flk-1 in the frontocortical tissues of 
WKY, SHR, and SHRSP for all ages, as demonstrated by the 
typical immunoblots and the cumulative data for quantitative 
immunoblotting, are shown in Fig. 3A and B, respectively. 
Expression of VEGF and Flk-1 in WKY was not affected by 
age, whereas in SHRSP, there was a pronounced increase, 
relative to WKY, between 6 to 20 weeks of age. However, the 
expression pattern in SHR was different from SHRSP. Between 
35–40 weeks of age, levels of VEGF and Flk-1 in the frontal 
cortex of SHRSP decreased by 50% relative to WKY (Fig. 3A 
and B). The protein expressions for VEGF and Flk-1 were 
consistent with mRNA levels obtained from real-time PCR 
(data not shown). 
3.5. Expression of pAkt and eNOS 
Typical immunoblots of pAkt and eNOS in the frontocortex 
of WKY, SHR, and SHRSP, at all ages examined, and the 
cumulative data for quantitative immunoblotting, are shown in 
Fig. 4A and B, respectively. In SHRSP, pAkt and eNOS ex- 
pressions were significantly less than in WKY between 6 to 
Fig. 5. (A), Morphology of cerebral capillaries in frontal cortex sections from WKYand SHRSP at 40 weeks of age. Photomicrographs of frontal cortex sections stained with 
lectin appearing as black/dark brown dots are shown. Magnification ×400. (B), Representative immunohistochemical image of VEGF (red color) in frontocortical tissues 
from WKY at 40 weeks of age. (C), Representative immunohistochemical image of endothelin-1 (red color) in frontocortical tissues from SHRSP at 40 weeks of age. 
Magnification ×400. 
40 weeks of age, with a marked decrease between 20 and 
40 weeks of age (Fig. 4A and B). 
3.6. Capillary morphology 
Capillary density in the frontal cortex of 40 week-old SHRSP 
rats, as determined by GS4 lectin staining, was significantly 
lower (43%) compared to age-matched genetic control WKYs 
(p 0.001) (Fig. 5A). At the typical hypertensive stage (18– 
20 weeks old), the capillary density in frontal cortex of SHRSP 
rats was slightly decreased (17%) compared to age-matched 
WKY rats (p 0.01). 
3.7. Cellular localization of Endothelin-1 and VEGF system 
The expression of endothelin-1, endothelin receptors, VEGF 
and the components of its angiogenic signaling transduction 
(Flk-1, pAkt and eNOS) were expressed abundantly in both the 
Fig. 6. Effects of endothelin receptor antagonist on (A) systolic blood pressure, (B) diastolic blood pressure, (C) regional cerebral blood flow, and frontocortical (D) 
endothelin-1 levels by ELISA in WKY, vehicle-treated SHRSP (SHRSP), and endothelin receptor antagonist-treated SHRSP (SHRSP+ SB209670) rats. Protein 
expressions of endothelin ETA receptor (E) and endothelin ETB receptor (F) in the frontocortical tissues from WKY, vehicle-treated SHRSP (SHRSP), and endothelin 
receptor antagonist-treated SHRSP (SHRSP+ SB209670) rats. The panel of bands, just above the histogram, shows representative blots of the type of animal, as 
described above. In each of the experiments, the band obtained from WKY is normalized as 1.0. Data are shown as means± S.D. of seven separate experiments. 
⁎p 0.01 vs. age-matched WKY, #p 0.01 vs. vehicle-treated SHRSP.
vascular and neuronal tissues of the frontal cortex (Fig. 5B and 
C). Moreover, in some cases, the expression was also localized 
in glial cells. 
Part 2 summarizes the effects of endothelin receptor antag- 
onism on different end-points or parameters investigated in 
SHRSP rats. 
3.8. Blood pressure 
After endothelin receptor antagonism, although the de- 
crease in systolic blood pressure of SHRSP rats appeared to be 
slight, it was statistically significant (p 0.05) (Fig. 6A). 
However, the diastolic blood pressure remained unchanged 
(SHRSP rats) after endothelin receptor antagonism (WKY: 
SHRSP: SHRSP+ 209670: 96 ± 2: 144 ± 8: 138 ± 18 mmHg) 
(Fig. 6B). 
3.9. Regional cerebral blood flow 
Although the regional CBF at 20 weeks of age in the frontal 
cortex of SHRSP tended to decrease, as shown previously 
in Fig. 1C, it was statistically insignificant. After endothelin 
receptor antagonism, the regional cerebral blood flow showed 
an apparent improvement, which was also statistically insignif- 
icant (Fig. 6C). 
3.10. Endothelin-1 level and expression of endothelin receptors 
Endothelin receptor antagonist normalized altered (up regu- 
lated) levels of endothelin-1 in the frontal cortex of SHRSP 
(Fig. 6D), as well as that of endothelin receptors, after a 
12-week treatment (Fig. 6E and F). The protein expressions 
of endothelin receptors were consistent with mRNA levels 
(data not shown). 
3.11. Expression of VEGF and Flk-1 
The three months treatments with dual endothelin re- 
ceptor blocker, starting from 6 weeks of age (pre-hyperten- 
sive stage) normalized levels of VEGF and Flk-1 in frontal 
cortex of SHRSP compared to those of WKY (Fig. 7A 
and B). 
Fig. 7. Protein expressions of VEGF (A), Flk-1 (B), pAkt (C) and eNOS (D) in the frontocortical tissues from WKY, vehicle-treated SHRSP (SHRSP), and endothelin 
receptor antagonist-treated SHRSP (SHRSP+ SB209670) rats. The panel of bands, just above the histogram, shows representative blots of the type of animal, as 
described above. In each of the experiments, the band obtained from control WKY is normalized as 1.0. Data are shown as means± S.D. of seven separate experiments. 
⁎p 0.01 vs. age-matched WKY, #p 0.01 vs. vehicle-treated SHRSP.
3.12. Expression of pAkt and eNOS 
Long-term treatment with dual endothelin receptor blocker 
normalized the immunoreactivity of pAkt and eNOS in 
frontal cortex in SHRSP compared to those in WKY (Fig. 7C 
and D). 
3.13. Capillary morphology 
The slight decrease in the capillary density of the frontal 
cortex in SHRSP rats was ameliorated by endothelin receptor 
antagonist. 
Part 3 summarizes the effects of endothelin receptor 
antagonism on different parameters in WKY rats. When control 
WKY rats were treated with SB209670, both the systolic and 
diastolic blood pressure tended to decrease. However, this 
change was statistically insignificant (Fig. 8A and B). Treat- 
ment of WKY rats with SB209670 also did not have any effect 
on the cerebral expression of endothelin receptors and com- 
ponents of VEGF signaling (Fig. 8). 
4. Discussion
One of the major findings of the present study is the 
demonstration that levels of VEGF and its angiogenic receptor, 
Flk-1, are altered age-dependently in the frontal cortex of 
SHRSP, i.e., they decreased slightly during pre-hypertension 
(6 weeks); significantly increased during the typical hyperten- 
sion (10–20 weeks); and markedly decreased during the 
malignant hypertension (35–40 weeks). On the other hand, 
levels of endothelin-1 and endothelin ETA receptor, were up- 
regulated during the three stages of hypertension, while 
Fig. 8. Effects of endothelin receptor antagonist on (A) systolic blood pressure, (B) diastolic blood pressure, frontocortical protein expression of (C) endothelin ETA 
receptor, (D) endothelin ETB receptor, (E) VEGF, (F) Flk-1, (G) pAkt and (H) eNOS in vehicle-treated WKY (WKY), and endothelin receptor antagonist-treated 
WKY (WKY+ SB209670) rats. The panel of bands, just above the histogram, shows representative blots of the type of animal, as described above. In each of the 
experiments, the band obtained from WKY is normalized as 1.0. Data are shown as means± S.D. of six separate experiments. 
endothelin ETB receptor was down regulated in a time- 
dependent manner. Moreover, there was a decline in frontal 
cortical blood flow at the typical hypertensive stage, which 
became remarkably significant at malignant hypertension. 
Further, the capillary density in the frontal cortex of SHRSP 
brain was also remarkably lower compared to the age-matched 
WKY rats at malignant hypertension. Of interest, endothelin 
receptor antagonism for three months, starting from the 
prehypertensive stage, significantly normalized levels of both 
VEGF and endothelin-1 signaling components compared to 
WKY control and slightly lowered the systolic blood pressure, 
without altering diastolic blood pressure in SHRSP rats. In 
contrast, endothelin receptor antagonism in WKY rats failed to 
reduce both the systolic and diastolic blood pressure 
significantly. 
Because SHRSP and SHR are nearly equally hypertensive at 
typical hypertensive stage, the differences in the profiles of 
angiogenic factors (VEGF and its signaling molecules) are 
unlikely to be due to elevated blood pressure. Levels of VEGF, 
along with its signaling molecules, are likely to be altered in 
abnormal regional cerebral blood flow (Jesmin et al., 2004). 
Because Akt plays a role in diverse cellular processes that 
contribute to the angiogenic process, its status within 
endothelial cells is critical for blood vessel growth (Kureishi 
et al., 2000; Shiojima and Walsh, 2002). The importance of 
eNOS in VEGF signaling is well documented (Ziche et al., 
1997; Paxian et al., 2004). Impaired angiogenesis in eNOS- 
knockout mice is not improved by giving VEGF (Kimura and 
Esumi, 2003) and in vitro studies have shown that VEGF- 
induced endothelial cell migration and proliferation can be 
significantly depressed by inhibition of eNOS action (Shizu- 
kuda et al., 1999; Murohara et al., 1999). Thus, Akt and eNOS 
are essential mediators in the angiogenic signaling cascade of 
VEGF. The simultaneous reduction in VEGF-signaling, regional 
cerebral blood flow and capillary density during the malignant 
hypertensive stage, a phase that precede stroke, may potentially 
create conditions that favor the pathogenesis of stroke in this 
animal model. To the best of our knowledge, the present study 
provides the first report showing a time-dependent alteration of 
VEGF signaling pathway and regional cerebral blood flow in the 
frontocortex of SHRSP. 
Factors likely to underlie hypertension include endothelial 
damage and abnormality in angiogenesis, which correlate with 
the overall cardiovascular and cerebrovascular risks (Felmeden 
et al., 2003). Another concept of impaired vascular develop- 
ment suggests structural alterations of microvascular beds, such 
as capillary rarefaction. Because angiogenic growth factors, are 
major regulators of blood vessel formation, such abnormal 
changes in angiogenesis are ultimately associated with altered 
expressions of these markers (angiogenic factors) (Hutchins and 
Darnell, 1994; Sullivan et al., 1983; Virgintino et al., 2003). For 
instance, evidence of angiogenesis in full-blown atherosclerosis 
includes increased numbers of vasa vasorum in arteries 
burdened with atheroma, which are associated with increased 
expression of angiogenic growth factors. Moreover, recent data 
demonstrated an increase in plasma levels of VEGF in hyper- 
tensive patients, suggesting that the impaired capacity for vas- 
cular growth may be related to abnormal regulation of VEGF 
(Felmeden et al., 2003). Here, we show that although VEGF and 
its angiogenic receptor are upregulated in SHRSP brain at 
typical hypertensive stage, the cerebral blood flow did not 
increase, but rather tended to decrease. Therefore, we speculate 
that there might be abnormal regulation of VEGF signaling, as 
well as abnormal vascular growth in the SHRSP brain, making 
it susceptible to stroke. Thus, it is crucial to arrest the defect in 
VEGF angiogenic signaling in frontal cortex prior to the 
development of malignant hypertension in SHRSP rats. 
The present finding shows an association between up- 
regulated levels of endothelin-1 and endothelin ETA receptor 
and vasoconstriction in SHRSP brain. It is of interest that this 
association was observed beginning from the pre-hypertensive- 
malignant stages, consistent with an earlier report that showed 
increased endothelin-1 binding in SHRSP brain (Savage and 
Jeng, 2002). In contrast to endothelin ETA receptor, endothelin 
ETB receptor, which mediates the vasodilatory properties of 
endothelin-1 (Seo et al., 1994), was down-regulated in SHRSP 
brain in an age-related manner. Thus, we argue that the aug- 
mented expression of endothelin-1 and endothelin ETA receptor 
in the frontal cortex of SHRSP contributes to various cere- 
brovascular remodeling that compromise blood flow volume. 
When endothelin ETA receptor causes vasoconstriction, endo- 
thelin ETB receptor activation induces endothelium-dependent 
relaxation through the release of NO and prostacyclin (Seo 
et al., 1994). The balance between vasoconstriction and vaso- 
relaxation or endothelin ETA receptor and endothelin ETB 
receptor is the most important factor in determining the regional 
blood flow and blood pressure regulatory effects of endothelin- 
1 (Schiffrin, 2001). This conclusion is consistent with a report 
by Armstead (Armstead, 2003) which stated that endothelin-1 
concentration is elevated in cerebrospinal fluid and contributes 
to the impaired cerebral hemodynamics following fluid per- 
cussion brain injury (FPI) in an age-dependent manner. Thus, 
we here suggest that suppression of VEGF angiogenic signaling 
cascade and the associated up regulation of endothelin-1/ 
endothelin ETA receptor in the frontal cortex of SHRSP rat, 
coupled with the development of malignant hypertension, may 
contribute to decreased regional cerebral blood flow and 
capillary microvasculature. Ultimately, this may lead to stroke. 
The therapeutic implications of these findings are that, at least in 
SHRSP rats, early reversal or correction of altered levels of 
VEGF and endothelin signaling is critical when performed prior 
to a significant drop in regional cerebral blood flow. 
In the second part of this study, we treated SHRSP rats with 
dual endothelin receptor antagonist for three months, starting 
from the prehypertensive stage, and found that endothelin 
antagonism greatly normalized the altered levels of VEGF and 
endothelin signaling in SHRSP brain. The normalization of 
these critical vasoregulatory pathways occurs at a stage when 
regional cerebral blood flow was not yet significantly com- 
promised, although a slight decrease in capillary density in 
frontal cortex was observed. Conflicting results exists on the 
interaction between VEGF and endothelin-1. Since its been 
shown that endothelin-1 induces VEGF mRNA expression 
through the endothelin ETA receptor in vascular smooth muscle 
cells (Pedram et al., 1997) and that endothelin-1 is able to 
induce angiogenic responses in cultured endothelial cells and 
stimulates neovascularization in vivo in concert with VEGF 
(Salani et al., 2000), we speculate that their altered relationship 
and interaction may contribute to the pathogenesis of the three 
stages of hypertension in SHRSP. If such a prediction is true, 
blockage of one of the two factors should normalize levels of 
either one or both VEGF and endothelin-1, and their associated 
molecules. Interestingly, consistent with our speculation, the 
signaling of both molecules was normalized by endothelin 
receptor antagonism. The exact mechanisms and/or relationship 
between the two angiogenic factors are currently unclear. It is 
possible that endothelin-1 alters levels of VEGF via mRNA 
transcription in vascular cells (Matsuura et al., 1998), and that 
increase in levels of endothelin-1 alters VEGF signaling and, 
subsequently, regional cerebral blood flow in SHRSP brain. 
Moreover, the interaction among the different components of 
endothelin system is complex and depends on a variety of 
factors. For instance, after endothelin receptor antagonism, 
levels of the unbound endothelin-1 seem to increase, even 
though those of the cerebral tissues and plasma are suppressed. 
In addition, endothelin receptor antagonism also reverses the 
alterations in endothelin receptors in frontal cortex of SHRSP 
rats. While complex feedback regulatory mechanisms persist 
among different components of endothelin system, at the same 
time other vasoregulatory molecules, such as nitric oxide, may 
also play a role in the regulation of endothelin-1 (Lavallee and 
Thorin, 2003; Schiffrin, 2001). 
The mechanisms that underlie the reversal effects of the dual 
endothelin receptor blocker on the various target molecules 
investigated here, may be non-hemodynamic since changes in 
the blood pressure in both SHRSP and WKY rats were not so 
different. Moreover, blockade of endothelin receptor in WKY 
rats did not alter either the components of VEGF signaling or 
endothelin receptors in the frontal cortex. Thus, it is reasonable 
to state that the effects of endothelin receptor blockade observed 
in SHRSP brain, is likely a specific event in SHRSP rats. 
However, we cannot at this point, based on the data obtained, 
delineate the specific mechanism that underlies the normaliza- 
tion or reversal of altered VEGF and endothelin-1 signaling by 
endothelin receptor antagonism in the SHRSP brain. Reversal of 
altered VEGF signaling cascade, accompanied by reduced 
cerebral endothelin-1, indicate that autocrine/paracrine endothe- 
lin-1 secretion pathways could be a factor in the neurovascular 
remodeling blunted by endothelin receptor antagonist. De- 
creases in regional endothelin-1 concentrations may also result 
from decreases in endothelin-1 production and/or increased 
endothelin-1 clearance. The production of endothelin-1 begins 
with the cleavage of the translational product preproendothelin-1 
(Lavallee and Thorin, 2003; Schiffrin, 2001) and our results 
show inhibition of endothelin receptor antagonist on preproen- 
dothelin-1 mRNA at the transcription levels (data not shown). 
Thus, decrease in endothelin-1 production may play a major role 
in regional endothelin-1 changes. Together, both secretion and 
synthesis of endothelin-1 may be inhibited by endothelin 
receptor antagonism, leading to reduced levels of endothelin-1 
and normalization of altered VEGF signaling cascade. More- 
over, it is our assumption that the blockade of endothelin ETA 
receptor may decrease levels of endothelin-1 due to the sup- 
pression of the positive feedback mechanism between endothe- 
lin-1 and endothelin ETA receptor. Enhanced endothelin-1 level 
has been shown to decrease endothelin ETB receptor activation 
and levels (Black et al., 1998). Thus, after endothelin receptor 
blockade, the cerebral endothelin ETB receptor level is 
normalized, likely due to the withdrawal effect of the inhibitory 
responses of the elevated endothelin-1 on cerebral endothelin 
ETB receptor expression. Endothelin-1 has been also shown to 
down regulate eNOS expression through endothelin ETA 
receptor (Wedgwood and Black, 2005). Thus, the decreased 
level of endothelin-1 by the dual receptor blocker might help in 
the recovery of eNOS expression in SHRSP brain. Indeed, 
coupling between endothelin ETB receptor stimulation and 
eNOS activation decreases sinusoidal constriction and plays a 
functionally important role in maintaining microcirculation and 
tissue oxygenation in the normal liver (Paxian et al., 2004). 
eNOS activity is increased only with endothelin ETA receptor 
plus endothelin ETB receptor antagonist, not by endothelin ETA 
receptor antagonist only, suggesting that endothelin ETB re- 
ceptor is associated with posttranscriptional regulation of NOS 
in hypercholesterolemia (Taner et al., 2001). Moreover, age- 
related dysregulation of nitric oxide-dependent mechanisms 
may also impact endothelin-1 responses (Besse et al., 2001; 
Lavallee and Thorin, 2003; Tschudi and Luscher, 1995). Be- 
cause nitric oxide (NO) may exert important inhibitory effects on 
endothelin-1 mediated signaling in some vascular beds (Laval- 
lee and Thorin, 2003), we speculated that aberrations in the 
functional cross-talk between endothelin receptors and NO 
might converge to exacerbate age-related and hypertension-de- 
pendent enhancements in endothelin-1-mediated cerebral con- 
strictor responses. However, future studies will aim to elucidate 
potential significant interactive effects between NO and endo- 
thelin receptor signal transduction pathways and their effects on 
the vascular dysregulation associated with aging and the 
progression of hypertension. 
The present study used a dual endothelin receptor blocker to 
see the changes in different target molecules in SHRSP brain. 
To further consolidate the hypothesis of the present investiga- 
tion, future studies should use specific endothelin receptor 
antagonist. Moreover, the measurement of regional cerebral 
blood flow was done in only four (n = 4) SHRSP rats after 
endothelin receptor antagonism. In order to arrive at a more 
convincing conclusion, the sample size of SHRSP rats should 
be increased and data obtained evaluated for regional cerebral 
blood flow after endothelin receptor antagonism. Lastly, the 
effect of endothelin receptor blocker in SHRSP rats should be 
performed prior to the time point when regional cerebral blood 
flow begins to significantly decline. 
In conclusion, SHRSP exhibits an age-dependent alteration 
in the signaling of VEGF in the frontal cortex. This alteration 
was accompanied by reduction in regional cerebral blood flow 
and up-regulation of endothelin-1 and endothelin ETA receptor. 
Administration of the dual endothelin receptor blocker nor- 
malized levels of both VEGF and endothelin-1, with their 
associated molecules. 
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